Search for:

In brief

On 30 April 2021, the Health Sciences Authority (HSA) Therapeutic Products Branch published its finalized guidance on the e-labelling of therapeutic products (TPs) in Singapore. The new guidance is effective from 30 April 2021.

Recommended actions

Product registrants interested in implementing e-labelling may file a notification form with the HSA online here. This online notification form should be submitted at least two months prior to actual implementation.

In more detail

On 30 April 2021, the HSA Therapeutic Products Branch published its finalised guidance on the e-labelling of TPs in Singapore. The new guidance is effective from 30 April 2021.

The documents, namely the updated Appendix 7 and 7a, may be found here.

The e-labelling initiative was first launched as a pilot trial in August 2019. It entails placing a machine-readable code or website URL on the TP’s packaging, which will link to a secure online system that publishes the package inserts and patient information leaflets in a digital format. This dispenses with the need to rely on a hardcopy insert typically contained within the packaging of the TP.

For further background on the e-labelling initiative, please see our December 2019 healthcare newsletter here.


Andy Leck is the managing principal of Baker McKenzie.Wong & Leow. Mr. Leck is recognised by the world’s leading industry and legal publications as a leader in his field. Asian Legal Business notes that he “always gives good, quick advice, [is] client-focused and has strong technical knowledge for his areas of practice”. Alongside his current role as managing principal, Mr. Leck has held several leadership positions in the Firm and externally as a leading IP practitioner. He currently serves on the International Trademark Association's Board of Directors and is a member of the Singapore Copyright Tribunal.


Ren Jun is an associate principal of Baker & McKenzie.Wong & Leow. Ren Jun extensively represents local and international intellectual property-intensive clients in both contentious and non-contentious IP matters, such as anti-counterfeiting; civil and criminal litigation; commercial issues; regulatory clearance; and advertising laws. Ren Jun also advises on a wide range of issues relating to the healthcare industries. These include regulatory compliance in respect of drugs, medical devices, clinical trials, health supplements and cosmetics; product liability and recall; and anti-corruption. Ren Jun is currently a member of the Firm's Asia Pacific Healthcare ASEAN Economic Community; Product Liability and Regulatory Sub-Committees.

Write A Comment